These findings support the cautious use of SGLT2 inhibitors in type 2 diabetes patients with DFD, emphasising their benefits in heart failure and CKD whilst avoiding canagliflozin in high‐risk groups. This evidence concerns the gene SLC5A2 and chronic kidney disease.